UniProt P01834
cetuximab Fab light chain (P01834)
cetuximab Fab light chain (UniProt P01834): 87 experimental structures on GenesisL1, 6 ligands bound, 89 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P01834
- Protein
- cetuximab Fab light chain
- Experimental structures
- 87
- Predicted models
- 0
- Ligands
- 6
- Pockets
- 89 · 15 records with a druggable one
Structures
87 records of P01834 in the MolNFT archive: 87 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1A4J | Diels alder catalytic antibody germline precursor | x-ray diffraction | L, A | — | — |
| 1A4J | Diels alder catalytic antibody germline precursor | x-ray diffraction | L, A | — | — |
| 1A4K | Diels alder catalytic antibody with transition state analogue | x-ray diffraction | L, A | — | — |
| 1A4K | Diels alder catalytic antibody with transition state analogue | x-ray diffraction | L, A | — | — |
| 1D5B | Unliganded mature oxy-cope catalytic antibody | x-ray diffraction | A, L | — | — |
| 1D5B | Unliganded mature oxy-cope catalytic antibody | x-ray diffraction | A, L | — | — |
| 1D5I | Unliganded germline precursor of an oxy-cope catalytic antibody | x-ray diffraction | L | — | — |
| 1D5I | Unliganded germline precursor of an oxy-cope catalytic antibody | x-ray diffraction | L | — | — |
| 1D6V | Conformation effects in biological catalysis introduced by oxy-cope antibody maturation | x-ray diffraction | L | — | — |
| 1D6V | Conformation effects in biological catalysis introduced by oxy-cope antibody maturation | x-ray diffraction | L | — | — |
| 1HKL | Free and liganded form of an esterolytic catalytic antibody | x-ray diffraction | L | — | — |
| 1HKL | Free and liganded form of an esterolytic catalytic antibody | x-ray diffraction | L | — | — |
| 1I7Z | Antibody GNC92H2 bound to ligand | x-ray diffraction | A, C | — | — |
| 1I7Z | Antibody GNC92H2 bound to ligand | x-ray diffraction | A, C | — | — |
| 1MIM | IgG Fab fragment (CD25-binding) | x-ray diffraction | L | — | — |
| 1MIM | IgG Fab fragment (CD25-binding) | x-ray diffraction | L | — | — |
| 1UCB | Structure of uncomplexed Fab compared to complex (1CLY, 1CLZ) | x-ray diffraction | L | — | — |
| 1UCB | Structure of uncomplexed Fab compared to complex (1CLY, 1CLZ) | x-ray diffraction | L | — | — |
| 3O11 | Anti-beta-amyloid antibody c706 fab in space group c2 | x-ray diffraction | L, A | — | — |
| 3O11 | Anti-beta-amyloid antibody C706 Fab in space group C2 | x-ray diffraction | L, A | — | — |
| 3QCT | Crystal structure of the humanized apo LT3015 anti-lysophosphatidic acid antibody Fab fragment | x-ray diffraction | L | — | — |
| 3QCT | Crystal structure of the humanized apo LT3015 anti-lysophosphatidic acid antibody Fab fragment | x-ray diffraction | L | — | — |
| 3QCU | Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (14:0) | x-ray diffraction | L, M | — | — |
| 3QCU | Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (14:0) | x-ray diffraction | L, M | — | — |
| 3QCV | Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (18:2) | x-ray diffraction | L, M | — | — |
| 3QCV | Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (18:2) | x-ray diffraction | L, M | — | — |
| 3U0W | AD related murine antibody Fragment | x-ray diffraction | L | — | — |
| 3U0W | Ad related murine antibody fragment | x-ray diffraction | L | — | — |
| 3U7W | Crystal structure of NIH45-46 Fab | x-ray diffraction | L | — | — |
| 3U7W | Crystal structure of NIH45-46 Fab | x-ray diffraction | L | — | — |
| 3U7Y | Structure of NIH45-46 Fab in complex with gp120 of 93TH057 HIV | x-ray diffraction | L | — | — |
| 3U7Y | Structure of NIH45-46 Fab in complex with GP120 of 93TH057 HIV | x-ray diffraction | L | — | — |
| 3VH8 | KIR3DL1 in complex with HLA-B*5701 | x-ray diffraction | C, F | — | — |
| 3VH8 | KIR3DL1 in complex with HLA-B*5701 | x-ray diffraction | C, F | — | — |
| 3X11 | Crystal structure of HLA-B*57:01.I80N.L82R.R83G | x-ray diffraction | C | — | — |
| 3X11 | Crystal structure of HLA-B*57:01.I80N.L82R.R83G | x-ray diffraction | C | — | — |
| 3X12 | Crystal structure of HLA-B*57:01.I80N | x-ray diffraction | C | — | — |
| 3X12 | Crystal structure of HLA-B*57:01.I80N | x-ray diffraction | C | — | — |
| 4D9R | Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D | x-ray diffraction | L, D | — | — |
| 4D9R | Inhibiting alternative pathway complement activation by targeting the exosite on factor D | x-ray diffraction | L, D | — | — |
| 4YDV | Structure of the antibody 7B2 that captures HIV-1 virions | x-ray diffraction | L, A | — | — |
| 4YDV | Structure of the antibody 7B2 that captures HIV-1 virions | x-ray diffraction | L, A | — | — |
| 5B38 | KIR3DL1*005 in complex with HLA-B*57:01 | x-ray diffraction | C | — | — |
| 5B38 | KIR3DL1*005 in complex with HLA-B*57:01 | x-ray diffraction | C | — | — |
| 5B39 | KIR3DL1*015 in complex with HLA-B*57:01 | x-ray diffraction | C | — | 1 (best 0.61) |
| 5B39 | KIR3DL1*015 in complex with HLA-B*57:01 | x-ray diffraction | C | — | — |
| 5C7K | Crystal structure BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies… | x-ray diffraction | F | — | — |
| 5C7K | Crystal structure BG505 sosip GP140 HIV-1 env trimer bound to broadly neutralizing antibodies… | x-ray diffraction | F | — | — |
| 5ESV | Crystal Structure of Broadly Neutralizing Antibody CH03, Isolated from Donor CH0219, in Complex… | x-ray diffraction | B, D, L | NAG, BMA, MAN | — |
| 5ESV | Crystal structure of broadly neutralizing antibody CH03, isolated from donor CH0219, in complex… | x-ray diffraction | B, D, L | — | — |
| 5ESZ | Crystal Structure of Broadly Neutralizing Antibody CH04, Isolated from Donor CH0219, in Complex… | x-ray diffraction | L, B | NAG, BMA, MAN | — |
| 5ESZ | Crystal structure of broadly neutralizing antibody CH04, isolated from donor CH0219, in complex… | x-ray diffraction | L, B | — | — |
| 5EWI | Crystal Structure of the Human Fab VRC38.01, an HIV-1 V1V2-Directed Neutralizing Antibody Isolated… | x-ray diffraction | L | — | 4 (best 0.60) |
| 5EWI | Crystal structure of the human Fab VRC38.01, an HIV-1 V1V2-directed neutralizing antibody isolated… | x-ray diffraction | L | — | — |
| 5VEB | Crystal structure of a Fab binding to extracellular domain 5 of Cadherin-6 | x-ray diffraction | B, L | — | — |
| 5VEB | Crystal structure of a Fab binding to extracellular domain 5 of cadherin-6 | x-ray diffraction | B, L | — | — |
| 5VIY | BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195 | electron microscopy | G, I | MAN, BMA | 2 (best 0.75) |
| 5VIY | BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195 | electron microscopy | G, I | MAN | — |
| 6AU5 | Structure of cetuximab with aminoheptanoic acid-linked n-butylarginine meditope variant | x-ray diffraction | A, C | SO4 | 8 (best 0.72) |
| 6AU5 | Structure of cetuximab with aminoheptanoic acid-linked N-butylarginine meditope variant | x-ray diffraction | A, C | SO4 | — |
27 records more on the page itself.
Ligands
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.